Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma
Liver International · 2024
DOI: 10.1111/liv.15918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Michihisa Moriguchi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background and Aims This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti‐platelet agents or anticoagulants.
Methods
Patients were divided into those using (IM out) and those not using (IM in) anti‐platelet agents or anticoagulants, who violated the exclusion criteria of the IMbrave150 trial, and were retrospectively examined.
Results
The study included 185 patients (IM in: 157; IM out: 28). For first‐line treatment, progression‐free survival was 184 days for IM in and 266 days for IM out ( p = .136). Overall survival was 603 days for IM in and not reached for IM out ( p = .265), with no significant between‐group difference. Similarly, there were no significant between‐group differences in progression‐free survival or overall survival for later‐line treatment. Haemorrhagic adverse events of ≥grade 3 were observed in 11 IM in patients and 3 IM out patients. No significant factors associated with haemorrhagic adverse events of ≥grade 3 were identified in the multivariate analysis including IM out classification, whose p value was .547. Regarding thrombotic/embolic adverse events in the IM out group, one case of exacerbation of portal vein thrombosis was observed. No deaths were directly attributable to bleeding events or exacerbations of thrombosis.
Conclusion
Atezolizumab + bevacizumab therapy shows similar safety and efficacy in patients receiving and those not receiving anti‐platelet agents or anticoagulants; therefore, it can be considered for patients with hepatocellular carcinoma receiving anti‐platelet agents or anticoagulants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
- Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
- Department of Gastroenterology, Kyoto City Hospital, Kyoto, Japan.
- Department of Gastroenterology, Fukuchiyama City Hospital, Kyoto, Japan.
ORCID-Profile: Michihisa Moriguchi, Yuya Seko, Kanji Yamaguchi
Zitieren
APA
Moriguchi, M., Okuda, K., Horiguchi, G., Kataoka, S., Seko, Y., Yamaguchi, K., Nishimura, T., Fujii, H., Mitsumoto, Y., Miyagawa, M., Kirishima, T., Okishio, S., Hara, T., Ishikawa, H., Nagao, Y., Jo, M., Ishii, M., Tanaka, S., Yamauchi, N., …, & Itoh, Y. (2024). Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma. Liver International. https://doi.org/10.1111/liv.15918
Vancouver
Moriguchi M, Okuda K, Horiguchi G, Kataoka S, Seko Y, Yamaguchi K, et al. Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma. Liver International. 2024. doi:10.1111/liv.15918
BibTeX
@article{Moriguchi2024,
author = {Moriguchi, Michihisa and Okuda, Keiichiro and Horiguchi, Go and Kataoka, Seita and Seko, Yuya and Yamaguchi, Kanji and Nishimura, Takeshi and Fujii, Hideki and Mitsumoto, Yasuhide and Miyagawa, Masami and Kirishima, Toshihiko and Okishio, Shinya and Hara, Tasuku and Ishikawa, Hiroki and Nagao, Yasuyuki and Jo, Masayasu and Ishii, Michiaki and Tanaka, Saiyu and Yamauchi, Norihito and Mitsuyoshi, Hironori and Nakajima, Tomoki and Taketani, Hiroyoshi and Yano, Kota and Arai, Masahiro and Umemura, Atsushi and Itoh, Yoshito},
title = {Safety/efficacy of atezolizumab + bevacizumab during anti‐platelet/anticoagulation therapy in unresectable hepatocellular carcinoma},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15918}
}
EUVIMED